Idorsia Ltd (LON:0RQE)

Market Cap	916.44M +652.7%
Revenue (ttm)	216.93M +213.7%
Net Income	-110.04M
EPS	-0.55
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,713
Average Volume	259,982
Open	3.895
Previous Close	3.931
Day's Range	3.865 - 3.975
52-Week Range	0.700 - 4.830
Beta	1.75
RSI	56.65
Earnings Date	Feb 26, 2026

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RQE

Financial Performance

In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.76 million, -11.47% less than in 2023.

Financial numbers in CHF